中國生物科技服務(08037.HK):上海隆耀CAR結構設計等專利申請已獲受理
格隆匯10月31日丨中國生物科技服務(08037.HK)發佈公告,公司非全資附屬上海隆耀生物科技有限公司(“上海隆耀”)與江蘇省人民醫院和徐州醫科大學附屬醫院(“徐醫附院”)開展了關於上海隆耀自主研發的新一代CD20靶向的自體CAR-T的研究者發起的臨牀研究。
根據披露的最近進展,產品設計上,該產品識別靶點為CD20,信號傳導部分採用上海隆耀自有知識產權的新型CAR結構設計。該靶點區別於CD19,為B細胞來源血液腫瘤患者,尤其是CD19CAR-T治療復發的CD19陰性的患者提供新的治療選擇。該新型CAR設計從激活強度上,提供更強的共刺激信號支持;從活化方式上,更好的模擬天然T細胞激活信號的時空特性。
在臨牀前實驗動物模型中,上海隆耀新一代CD20靶向CAR-T在小鼠體內顯示出優異的抗腫瘤活性,在腫瘤負荷控制,CAR-T細胞體內的擴增,都較臨牀廣泛使用的二代CAR結果有顯着提升,並且在性能提升的同時,未觀察到CAR-T導致的毒副作用。
上海隆耀研發的新型CAR結構對CAR-T功能的增強不侷限於血液瘤靶點,在針對實體瘤(肺癌,胰腺癌)的臨牀前動物模型,都顯示了類似的抗腫瘤活性提升,在臨牀實體瘤CAR-T治療方面具有廣闊的應用前景。
上海隆耀所獨有的信號傳導結構和CAR結構設計都已經申請了國內專利和PCT專利,並都已經獲得受理。除徐州醫科大學附屬醫院外,該項目在江蘇省人民醫院於2019年10月10日也已經正式啟動了研究者發起的臨牀研究,研究由血液科李建勇主任主持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.